Immuneering (IMRX) Non-Current Assets (2020 - 2026)
Immuneering (IMRX) posted quarterly Non-Current Assets of $53.4 million for Q1 2026, up 328.06% year-over-year from $12.5 million in Q1 2025, and down 4.2% quarter-over-quarter from $55.7 million in Q4 2025.
Immuneering (IMRX) Non-Current Assets (2020 - 2026) Analysis & Trends
Immuneering's Non-Current Assets history runs 7 years deep, the most recent figure standing at $53.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 328.06% year-over-year to $53.4 million; the TTM figure through Mar 2026 stood at $133.4 million (up 155.11% YoY), while the FY2025 annual figure was $55.7 million, up 324.62% from the prior year.
- Non-Current Assets for Q1 2026 stood at $53.4 million, down from $55.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $55.7 million in Q4 2025, with the low at $12.0 million in Q3 2025.
- The 5-year median for Non-Current Assets is $13.4 million (2023), against an average of $18.0 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 702.36% in 2022, then retreated 10.1% in 2025.
- Immuneering's Non-Current Assets stood at $13.6 million in 2022, then declined by 0.88% to $13.5 million in 2023, then fell by 2.77% to $13.1 million in 2024, then jumped by 324.62% to $55.7 million in 2025, then slipped by 4.2% to $53.4 million in 2026.
- Business Quant data shows IMRX's Non-Current Assets at $53.4 million in Q1 2026, $55.7 million in Q4 2025, and $12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 44.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.06 Mn |
| Mar 31, 2026 | 53.40 Mn |
| Dec 31, 2025 | 55.74 Mn |
| Sep 30, 2025 | 11.95 Mn |
| Jun 30, 2025 | 12.33 Mn |
| Mar 31, 2025 | 12.48 Mn |
| Dec 31, 2024 | 13.13 Mn |
| Sep 30, 2024 | 13.30 Mn |
| Jun 30, 2024 | 13.40 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 13.50 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 13.39 Mn |
| Mar 31, 2023 | 13.46 Mn |
| Dec 31, 2022 | 13.62 Mn |
| Sep 30, 2022 | 13.67 Mn |
| Jun 30, 2022 | 12.88 Mn |
| Mar 31, 2022 | 12.92 Mn |
| Dec 31, 2021 | 14.37 Mn |
| Sep 30, 2021 | 10.73 Mn |